Chronic HBV infection in "indefinite period"
Conditions
Interventions
Monotherapy with nucleos(t)ide analogues (NAs) for 52 weeks:None
Receiving peginterferon a-2b in combination with nucleos(t)ide analogues (NAs):None
Sponsors
Meishan City Peoples Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 60 Years
Inclusion criteria
Inclusion criteria: 1.Age 18-60 years old; 2.HBsAg positive for more than 6 months. 3.ALT =20iu/mL; 5.Initial treatment (NAs or interferon anti-HBV drugs have not been used before).
Exclusion criteria
Exclusion criteria: 1.Patients with chronic hepatitis B; 2.Patients with ALT > 1× ULN; 3.Liver fibrosis, liver cirrhosis, liver cancer and other malignant tumors; 4.Alcoholics or drug addicts; 5.Patients with HAV, HCV, HDV and HEV infection and autoimmune liver disease; 6.Pregnant and lactating women,Those who need to use interferon should be excluded from family planning within 2 years. 7.The competent physician thinks that it is not suitable to participate in this research; 8.It is included in the interferon whole course/pulse combined treatment group; 9.(1) Contraindications to interferon (2)autoimmune diseases, psychosis (depression, etc.), diabetes and abnormal thyroid function(3) serious basic diseases: cardiovascular diseases, lung diseases, kidney diseases, brain and fundus diseases (4)low leukocyte/leukocyte ratio in peripheral blood: < 2×10^9/L and/or platelet count < 100× 100.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| HBV DNA;HBsAg;HBeAg; | — |
Secondary
| Measure | Time frame |
|---|---|
| HBeAg seroconversion;The decrease/proportion of HBV-DNA, HBeAg, and HBsAg compared to baseline at the end of treatment;HBsAg seroconversion; | — |
Countries
China
Contacts
Public ContactLiu Jiahao
Meishan City Peoples Hospital
Outcome results
None listed